Invest in a Healthier World:
Building the Future of Early CAD Assessment
HeartForce™ is addressing one of healthcare’s largest unmet needs: the vast gap in early coronary artery disease (CAD) identification. Traditional diagnostic tools are reactive, costly, and limited to late-stage symptom confirmation. By delivering a proprietary, non-invasive, and cost-effective screening platform, HeartForce bridges clinical necessity with market opportunity.
As an investor, you are backing a scalable solution designed to lower healthcare system costs, improve patient outcomes, and establish a new standard of care in preventive cardiology.
Cost-Effective.
Universal Accessibility.
Secure Data Handling.
Regulatory & Commercial Action Plan
Regulatory Approvals
HeartForce is on track to secure EU MDR certification and Health Canada regulatory approval in Q1 2027, followed by FDA approval in Q4 2027.
Market Entry & Scale
Post-regulatory approval, immediate commercial rollout across primary care clinics, pharmacies, occupational health facilities, and cardiology departments in Europe and Canada.
Get in Touch
We welcome inquiries from institutional investors, strategic partners, and family offices. Contact our team to request our investor deck, see our CardioClin™ in action, or discuss our regulatory progress, commercialization strategy, and growth plans.
Direct Inquiries: ir@heartforce.com
